Overview

Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients

Status:
Withdrawn
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
Tranexamic Acid